Clinical-stage pharmaceutical company Cempra has commenced a Phase II trial evaluating CEM-102 in patients with prosthetic joint infections (PJIs).

CEM-102 is a novel class of antibiotic and the company’s loading dose formulation of fusidic acid, an orally-active anti-staphylococcal agent, with an established history of safety and efficacy outside the US.

FIDSA clinical research senior vice president Dr David Oldach said the all-oral antibiotic regimen allows the treatment of PJI offering convenient drug administration without the expense and morbidity of maintaining long term venous access.

“CEM-102 is a novel class of antibiotic and the company’s loading dose formulation of fusidic acid, an orally-active anti-staphylococcal agent, with an established history of safety and efficacy outside the US.”

“We hope that the results of this study will lead to a new option for these patients,” Oldach said.

The open-label trial will randomise 50 patients with either oral CEM-102 plus rifampin or current standard of care, which is intravenous antibiotic therapy with antibiotics including vancomycin, nafcillin or cefazolin.

Infection-free status at 12 weeks following initiation of therapy is the primary outcome of the trial, which is expected to deliver the top-line results during the fourth quarter of 2013.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Long-term monitoring for infection relapse or recurrence will continue for the following two years, according to the company.

Cempra president and chief executive officer Dr Prabhavathi Fernandes said; “Our clinical program of CEM-102 for PJI is an example of this mission along with solithromycin, which is about to enter Phase III clinical development for community-acquired bacterial pneumonia.”